← All trials
NCT01405573
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2011
- Primary completion
- Mar 1, 2017
- Completion date
- Mar 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 35
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fondazione Giovanni PascaleLead sponsor
- Azienda Sanitaria Rummo, Benevento, Division of Medical OncologyOverall official - principal investigator
- University of Campania Luigi VanvitelliOverall official - principal investigator
- Azienda Ospedaliera Antonio CardarelliOverall official - principal investigator
- Fondazione Giovanni PascaleOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.